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Abstract
Background: Inflammasomes and sphingosine-1-phosphate (S1P) signalling are increasingly subject to intensive
research in human diseases. We hypothesize that in respiratory muco-obstructive diseases, mucus obstruction
enhances NLRP3 inflammasome activation and dysregulated S1P signalling.
Methods: Lung tissues from mice overexpressing the beta-unit of the epithelial sodium channel (βENaC) and their
littermate controls were examined by histology, immunofluorescence and confocal microscopy, followed by ImageJ
quantitative analysis.
Results: Lower airways in βENaC mice showed patchy patterns of mucus obstruction and neutrophil-dominant
infiltrations. In contrast to a ubiquitous distribution of TNFα specks, significantly (p < 0.05) increased specks of
bronchiolar NLRP3, IL-1β, and IgG in the βENaC mouse lungs were localized to the vicinity of mucus obstruction
sites. Bright Spinster homologue 2 (SPNS2) at the epithelial apex and positive correlation with sphingosine kinase 1
(SPHK1) (R2 = 0.640; p < 0.001) supported the normal bronchial epithelium as an active generator of extracellular
S1P. SPNS2 in βENaC mice was sharply reduced (38%, p < 0.05) and lost apical localization at sites of mucus
obstruction. A significant (34%; p < 0.01) decrease in epithelial SPHK2 was also noted at mucus obstruction sites.
Conclusion: These results support that mucus obstruction may enhance NLRP3 inflammasome activation and
dysregulated S1P signaling.
Keywords: Inflammasome, Sphingosine-1 phosphate, Respiratory muco-obstructive diseases, Cystic fibrosis, Mouse
model
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Introduction
A common feature in cystic fibrosis (CF), chronic ob-
structive pulmonary disease (COPD), primary ciliary
dyskinesia and non-CF bronchiectasis is airway obstruc-
tion resulting from overproduction and dehydration of
mucus, giving these diseases the collective term ‘muco-
obstructive lung diseases’ [1]. Mucus obstruction causes
local hypoxia, favoring proliferation of facultative anaer-
obic pathogens including Pseudomonas aeruginosa,
Staphylococcus aureus, and Haemophilus influenzae
which maintain chronic airway inflammation and trigger
acute flares of the diseases. The hypoxic tissue milieu it-
self can also initiate a sterile inflammatory cascade [1].
The excessive lung inflammation in muco-obstructive
diseases involves elevated levels of pro-inflammatory cy-
tokines, with IL-1β, TNFα, IL-6 and IL-8 often detected
in bronchoalveolar lavage (BAL) or sputum of patients
[2–4]. Maturation and release of IL-1β and other cyto-
kines of the IL-1 class is regulated via activation of
inflammasomes; cytosolic multiprotein complexes aggre-
gated around a sentinel protein such as NLRP3
(NACHT, LRR and PYD domains-containing protein 3),
NLRC4 (NLR family CARD domain-containing protein
4) and AIM2 (absent in melanoma 2). It is not always
feasible to differentiate sterile from pathogen-induced
inflammation in clinical presentations of muco-
obstructive disease. Previous studies showed that signal-
ling via the IL-1R/MyD88 axis is indispensable in the in-
flammatory response by the airway epithelium and
neutrophils to mucus obstruction-associated hypoxia [5,
6]. Although activation of inflammasome(s) by mucus
obstruction, upstream of the IL-1R/MyD88 signalling, is
likely in these settings, little is known about the nature
of the inflammasome(s) involved.
Sphingosine-1-phosphate (S1P) is a small bioactive
lipid that regulates many cellular processes. Generation
of S1P inside the cell from sphingosine is mediated by
two sphingosine kinases (SPHKs), SPHK1 mostly in
cytosol, and SPHK2 in intracellular organelles. S1P sig-
nalling leads to diverse or even opposing cellular effects,
via intracellular targets, or membrane-bound receptors
S1PR1–5 at the cell surface (‘inside-out’ S1P signalling
[7]). In the latter pathway, S1P is exported via some
membrane transporters, of which Spinster homologue 2
(SPNS2) has recently been shown to be functional in
physiologic settings [8]. S1P signalling is part of the
‘sphingolipid rheostat’ regulatory system in which S1P
and ceramides and sphingosine usually induce effects
opposing to each other [7]. Increase in ceramides is a
common feature and potential cause of the increased cell
death, inflammation and susceptibility to infections in
the airway of muco-obstructive diseases including CF,
COPD and cigarette smoke-induced inflammation [9–
12]. Relevant to a mechanistic relationship between
inflammasome pathways and sphingolipid signalling,
intracellular ceramides have been shown to be directly
sensed by the NLRP3 inflammasome [13]. Less is known
on the alteration of S1P signalling and its role in muco-
obstructive diseases. Previous studies by us and others
indicated complex dysregulation of the S1P signalling
system in COPD (and in response to cigarette smoke)
involving several components and various cell types
[14–16]. Large gaps in this field remain, especially
whether and how individual components of the S1P sig-
nalling system are dysregulated in diseases such as CF,
COPD, non-CF bronchiectasis, and whether mucus ob-
struction directly contributes to this dysregulation. .
In this study we employed a well-characterized mouse
model of muco-obstructive disease elicited by overex-
pression of the beta-unit of the epithelial sodium chan-
nel (βENaC) specifically in the airway [17] to explore the
hypothesis that mucus obstruction can enhance both




Primary antibodies included rabbit polyclonal to SPHK1
and SPHK2 (Bs-2652R and Bs-2653R, Bioss, Woburn,
MA, USA, both 1:50), NLRP3 and IL-1β (sc-66,846 and
sc-7884, Santa Cruz, Dallas, TX, USA, both 1:40),
GLUT1 (Glucose Transporter 1, ab652, Abcam, Cam-
bridge, UK, 1:100), goat polyclonal antibody to SPNS2
(sc-165,572, Santa Cruz, 1:40), TNFα (sc-1348, Santa
Cruz, 1:50), myeloperoxidase (#2141, Osenses, Adelaide,
SA, Australia, 1:100), and a mouse monoclonal antibody
to neutrophil elastase (M0752, Dako GmbH, Jena,
Germany, 1:100). Conjugated antibodies (1:150) were F
(ab’)2 fragments of donkey IgG, obtained from Jackson
ImmunoReseach (West Grove, PA, USA), anti-rabbit
IgG (Alexa Fluor 594 or Alexa Fluor 488), anti-goat IgG
(Alexa Fluor 488), and anti-mouse IgG (Alexa Fluor
647).
Mouse model
Archived mouse lung tissues of βENaC-overexpressing
mice (blocks from four animals, and pre-cut sections
from another four, total n = 8) and their age/gender-
matched wild type controls (blocks from three animals
and pre-cut sections from another three, total n = 6)
were retrieved from a previously published study ap-
proved by the Animal Ethics Committees at Women’s
and Children’s Health Network, Adelaide, South
Australia, and the University of Adelaide [18]. The mice
originated from a mixed genetic background (C3H/HeN
x C57Bl/6 N bred with male C3B6F1 wild-type). Mouse
lungs were inflation fixed using 10% neutral buffered
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formalin (NBF), excised from the animals, fixed in NBF
for a further 24 h, and processed into paraffin blocks.
Quantitative immunofluorescence
Tissue sections were examined for protein expression
and subcellular localization by immunofluorescence fol-
lowing a protocol adapted from our previous study of
inflammasome activation in a mouse model of allergic
inflammation [19]. Tissue sections cut at 5 μm thickness
were mounted in tissue arrays (single section from each
animal, 4 sections per array), so all animals could be ex-
amined in parallel and no batch controls of intensity
were required. The signal intensity of each marker was
controlled by antibody titrations in preliminary
experiments. The fluorescence digital intensities in the
confocal images were controlled by setting the laser
power (0.1 to 5%), voltage and digital gain, so that when
a uniform setting was applied to all samples (including
the negative controls) in each batch, the dullest samples
well exceeded the negative staining controls, while the
brightest samples did not reach digital saturation. In
each batch, the negative staining controls included sec-
tions incubated with only the mix of three secondary
antibodies (anti-rabbit IgG AF594, anti-goat IgG AF488,
anti-mouse IgG AF647). Ten to 20 independent bronchi-
oles in each sample were photographed from an area of
0. 3-0.5 cm2 under a 60x objective of a FV3000 confocal
system (Olympus Corporation, Shinzuku, Tokyo, Japan).
Fig. 1 βENaC overexpression induced mucus obstruction and myeloid infiltration. a, b Representative NanoZoomer scans of Alcian Blue/PAS
staining in wild type (A, n = 5) and βENaC (B, n = 6) mouse lungs. Scales are in micrometers. c Quantitation of mucus obstruction and (d)
Quantitation of myeloid infiltration in wild type and βENaC mouse lungs. Dots represent mean values from individual animals. Mann-Whitney, *
p < 0.05; ** p < 0.01
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The optical fields were selected in the DAPI channel to
prevent bias. Monochromatic photographs were ana-
lysed using the ImageJ software (NIH, Bethesda, MA,
USA). For quantitative analysis, the mean fluorescence
intensity (MFI) of staining in the bronchial epithelia was
measured from each photo and the background intensity
of the relevant negative control was subtracted. A mean
value from at least 10 images was then calculated for
each animal. For analysis of strongly heterogeneous
staining as for TNF-α, IL-1β and NLRP3, a lower thresh-
old of intensity was set relatively high to gate out dull/
moderate fluorescence (below the threshold) from bright
specks, which were then counted using the “particle ana-
lysis” function, and normalized to number of nuclei
counted in the DAPI channel.
Histology
For exact histological localization of immunostaining pat-
terns, following confocal imaging, sections were re-stained
with Alcian Blue/PAS or H&E, then scanned with a Nano-
Zoomer digital slide scanner (Hamamatsu Photonics, Ha-
mamatsu, Shizuoka, Japan). Mucus plaques or plugs seen
under confocal microscopy as intraluminal nonstructural
masses were all confirmed in Alcian Blue/PAS scans.
Levels of mucus obstruction were measured by percentage
ratio between Alcian Blue/PAS-positive bronchiolar sites
and the total number of bronchiolar sites in each lung sec-
tion. Myeloid foci containing more than 20 nuclei were
counted from whole scans, then normalized to lung area
in square centimeters.
Statistical analysis
Data was analysed using Wilcoxon signed-rank tests,
Mann-Whitney tests, paired t-tests and Spearman’s cor-
relation as appropriate, and were performed using Prism
software (GraphPad Software Inc., California, USA).
Results
βENaC overexpression induced patchy mucus obstruction
and neutrophil-dominant infiltration in mouse airways
Comparison of βENaC-overexpressing mice to wild type
controls confirmed substantial induction of airway
mucus obstruction seen as plaques on bronchiolar lu-
minal surfaces and masses plugging parts of bronchioles
(Fig. 1). In accordance with our previous finding of lung
function heterogeneity in βENaC mice [18], mucus ob-
struction in their lungs revealed patchy patterns. Within
the same βENaC lung, parts of the bronchioles looked
Fig. 2 Neutrophil infiltration in the airway of βENaC-overexpressing mice. (A) Representative confocal images of neutrophils, identified by high
expression of neutrophil elastase (red) and myeloperoxidase (green). Shown are neutrophils that are intravascular (a), attached to the vascular
inner wall (b), and extravasated (c). (B-D) Representative confocal images of neutrophils identified by high expression of myeloperoxidase (green)
and lobular shape of nuclei (Blue, DAPI). Shown are neutrophils that are intravascular in a wild type control (B), in submucosal tissue near a
relatively intact bronchiole of a βENaC animal (C), and infiltrating a mucus plug in a βENaC animal (D). Scale bars are in micrometers
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relatively intact while others were seen with mucus pla-
ques, or entirely plugged with mucus (Fig. 1b). The
βENaC lung revealed leucocyte infiltration seen as com-
pact foci in submucosal parenchyma, and cells diffused in
mucus (Fig. 1b). Quantitative analysis of whole NanoZoo-
mer scans confirmed statistically significant increases in
both mucus obstruction and infiltration foci in βENaC
lungs compared to controls (Fig. 1c, d). Using neutrophil
markers myeloperoxidase and neutrophil elastase, leuco-
cyte infiltration of mucus plaques and plugs was shown to
be neutrophil-dominant (Fig. 2). Levels of airway mucus
obstruction and inflammatory infiltration of individual
mice are given in Table S1, together with their genotypes,
genders, body mass, and age at termination.
NLRP3 inflammasome activation but not TNFα in the
lungs of βENaC mice was associated with patchy mucus
obstruction
We next studied pro-inflammatory changes in lungs of
βENaC-overexpressing mice by quantitative
immunofluorescence analysis of IL-1β and TNFα
localization. As normal mouse airway epithelia always
show dull/moderate staining of cytokines and inflam-
masome proteins, quantitative particle analysis by
ImageJ was applied to screen in only bright immuno-
fluorescence specks. In line with previous findings
that lung inflammation in βENaC-overexpressing mice
is driven by TNFα [20], increased bright speck stain-
ing of this cytokine was detected globally in the lungs
of βENaC-overexpressing mice compared to control
animals. Bright TNFα staining was localized to alveoli
and bronchioles, irrespective of mucus obstruction
(Fig. 3). Compared to TNFα, distribution of NLRP3
and IL-1β specks showed a marked difference. While
the wild type control bronchiolar epithelia (as well as
unobstructed bronchiolar epithelia of the tested
βENaC animals) revealed only small, sporadic specks
with predominantly homogenous fluorescence of
NLRP3, increased speck staining for NLRP3 was de-
tected at the apical epithelial surface near mucus
Fig. 3 Global increase in TNF-α in the βENAC mouse lung was not associated with mucus obstruction. TNF-α was labelled in green, nuclei counterstained
with DAPI (blue), scale bars are in micrometers, insets are magnification of the boxed areas. Wild type control alveoli (a) and bronchiolar epithelium (d)
showed few small size specks of TNF-α (arrowheads). βENAC alveoli (b) and bronchiolar epithelium (e, f) showed increased TNF-α specks, irrespective of
being unobstructed (e) or obstructed (f) with mucus. c Negative staining control. g Box plot represents mean values of bronchioles’ speck numbers
normalized to numbers of nuclei, measured from individual mice; βENaC animals are present with two sets of data corresponding to unobstructed (red)
and obstructed (green) areas. Each dot in the box plots represent the average of 10 bronchioles. Mann-Whitney, ** p< 0.01
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plugs and plaques, and in intraluminal mucus masses
(Fig. 4 and Fig. S1). Similar patterns of increased
speck immunofluorescence associated with mucus ob-
struction were observed for IL-1β, which was shown
localized to the same site as NLRP3 in consecutive
serial sections (Fig. 5). Infiltrating cells in mucus
plaques and plugs were often seen associated with in-
creased NLRP3 and IL-1β (Figs. 4 and 5). The epithe-
lium at and near the mucus obstruction sites
displayed a trend to increased apical immunofluores-
cence of glucose transporter-1 (GLUT1, a marker of
hypoxia), while endogenous IgG was highly
Fig. 4 Speck immunofluorescence of NLRP3 was associated with mucus obstruction in βENaC airways. a-d Representative confocal images of
NLRP3 (red). a Wild type control tissue showed mostly homogeneous NLRP3 staining and few sporadic small size specks of NLRP3 (arrowheads,
inset is magnification of the boxed area). b βENaC unobstructed bronchiolar epithelium showed no significant increase in specks (arrowheads)
compared to wild type control. c βENaC bronchiolar epithelium near a mucus plaque showed increased speck staining near and at the apical
surface (arrowheads). d βENaC bronchiole plugged with mucus showed increased speck staining at the epithelial apex (arrowheads), and in the
mucus plug which contained leucocytes (short arrow). For confirmation of mucus plaques/plugs in B-D please refer to Supplementary Data
Figure S1. Nuclei counterstained with DAPI (blue), scale bars are in micrometers. e Box plot represents mean values of bronchioles’ speck
numbers normalized to numbers of nuclei, measured from individual mice; βENaC animals are present with two sets of data corresponding to
unobstructed (red) and obstructed (green) areas. Each dot in box plots represent the average of 10 bronchioles. Mann-Whitney, ** p < 0.01
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distributed in mucus plaques and plugs (Figs. S2, S3).
Negative control staining inserted in each batch
showed no nonspecific binding of conjugated anti-
bodies to mucus and other tissues (Fig. S4). Thus, un-
like the increase in TNFα specks which showed
global distribution in βENaC airways, increased specks
of NLRP3, IL-1β, and intraluminal IgG were confined
to airways at or near sites of mucus obstruction.
βENaC overexpression induced mucus obstruction-
associated reduction of SPNS2 expression
The most abundant expression of SPNS2 protein in
mouse lungs was localized to bronchial and bronchiolar
epithelium where it was detected as dotty immunofluor-
escence near the lateral membranes and as intense
patches at the epithelial apex. Measurement of SPNS2
immunofluorescence in bronchiolar epithelia varied
Fig. 5 Increased immunofluorescence specks of IL-1β in bronchioles of βENaC mice associated with mucus obstruction. a-d Representative
confocal images of IL-1β (red), nuclei stained with DAPI (blue), scale bars are in micrometers. Wild type control (a) and βENaC unobstructed
bronchioles (b) showed mostly homogenous immunofluorescence in the epithelium. c and d βENaC obstructed bronchioles showed increased
speck staining of IL-1β; (e) IL-1β (left) localized to the same places as NLRP3 (right) in adjacent serial sections. Short arrows indicate increased IL-
1β around intraluminal leucocytes; arrowheads: increased IL-1β at epithelial surface. f Box plot represents mean values of bronchioles’ speck
numbers normalized to numbers of nuclei, measured from individual mice; βENaC animals are present with two sets of data corresponding to
unobstructed (red) and obstructed (green) areas. Each dot in box plots represent the average of 10 bronchioles. Mann-Whitney, * p < 0.01
Tran et al. Journal of Inflammation           (2020) 17:16 Page 7 of 12
Fig. 6 βENaC overexpression induced reduction of bronchiolar epithelial SPNS2 expression associated with mucus obstruction. a-d Representative
confocal images of SPNS2 (green) in (a) wild type control, (b) βENaC unobstructed, versus (c) obstructed bronchiole; (d) a negative staining
control showing no binding of AF488-conjugated anti-goat IgG. Blue is labelling of nuclei by DAPI. Scale bars are in micrometers. e Box plot
represents MFI values of SPNS2 expression measured from individual βENaC mice, unobstructed (red) versus mucus obstructed (green)
bronchioles. Mann-Whitney, * p < 0.05. Each dot represents the average of 10 bronchioles
Fig. 7 Colocalization and correlation of SPHK1 expression with SPNS2. a Representative confocal images of a control animal bronchiole showing
colocalization of SPHK1 (red) and SPNS2 (green). Yellow is merged color of red and green. Blue is DAPI. Scale bars are in micrometers. b Positive
Spearman’s correlation between MFI of SPHK1 and SPNS2 in both unobstructed (red; r = 0.640; p < 0.001; n = 62 bronchioles from 7 mice) and
mucus obstructed (green; r = 0.745; p < 0.001; n = 42 bronchioles from 4 mice)
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greatly within each animal and among animals of the
same genotype, reaching no statistically significant
changes in mean intensity between the βENaC and con-
trol mice. However, on further analysis, a significant re-
duction in MFI was demonstrated in bronchiolar
epithelia associated with mucus obstruction, compared
to unobstructed epithelia (Fig. 6).
Bronchiolar epithelial SPHK1 was co-localized and
correlated with SPNS2
The wild type control and βENaC mouse lungs
showed ubiquitous expression of SPHK1, with the
brightest immunofluorescence localized to bronchi-
olar epithelium. In addition, moderate staining was
also detected in vascular endothelium and smooth
muscle, alveolar macrophages and unidentified leuco-
cytes (Fig. 7). Of note in the bronchioles, particulate
immunofluorescence of SPHK1 was co-localized with
SPNS2 and was most intense at the epithelial apex
(Fig. 7a). Quantitative analysis revealed a significant
positive correlation between SPHK1 and SPNS2
(Fig. 7b). Epithelial expression of SPHK1 in βENaC
mice showed no significant change compared to con-
trol animals, or change associated with mucus ob-
struction (Fig. S5).
βENaC overexpression induced downregulation of
bronchiolar epithelial SPHK2
Bright immunofluorescence of SPHK2 was observed in
distal airways of both control and βENaC mice, localized
to alveolar walls and alveolar macrophages (Fig. S6).
SPHK2-bright cells were also often detected near bron-
chiolar epithelial apices or in luminal mucus (Fig. 8, in-
sets). Moderate cytoplasmic staining of SPHK2 was
shown throughout the bronchiolar epithelial layers with
punctate dots revealed in a subpopulation of cells (Fig. 8,
inset). Quantitative analysis of bronchiolar epithelia re-
vealed a non-significant trend of reduction of SPHK2 in
βENaC mice compared to controls, and a significant re-
duction in mucus obstruction-associated epithelia com-
pared to those without mucus obstruction (Fig. 8).
Discussion
This study presents findings from a mouse model of air-
way mucus dehydration and obstruction elicited by over-
expression of an epithelial ion channel, βENaC, which
support a hypothesis that NLRP3 inflammasome activa-
tion and dysregulated S1P signalling are associated with
mucus obstruction, the common pathologic component
in CF, COPD and other muco-obstructive diseases (sum-
marized in Fig. 9). Increased bright specks of NLRP3
and IL-1β detected in the lung of βENaC overexpressing
mice were highly localized to the vicinity of mucus
Fig. 8 βENaC overexpression-induced reduction of bronchiolar epithelial SPHK2 expression associated with mucus obstruction. a-c Representative
confocal images of SPHK2 immunofluorescence (red) in control (a) and βENaC mouse lungs, unobstructed (b) vs. obstructed airway (c). d A
negative staining control shows no binding of AF594-conjugated anti-rabbit IgG (red). The insets are magnification of boxed areas. Blue is DAPI.
Scale bars are in micrometres. e Box plot represents MFI values of SPHK2 expression measured from individual βENaC mice in unobstructed (red)
versus mucus obstructed (green) epithelia (Mann-Whitney, p < 0.01). f Dot plot showing the same data paired for each βENaC mouse (paired t-
test, p < 0.05). Each dot in E and F represent the average of 10 bronchioles
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plaques and plugs. Specks vs. homogenous fluores-
cence reflects oligomeric vs. monomeric states and is
a method for the detection of NLRP3 inflammasome
activation [21]. In the lungs, measurement of IL-1β/
IL-18 in BAL is a commonly accepted technique to
detect inflammasome activation, particularly in mouse
studies [22]. Due to unavailability of BAL samples,
the mentioned approach could not be done in this
study, although detection of IL-1β in luminal spaces
or at epithelial surfaces indicated the cytokine release.
Next, although apical membrane patterns of NLRP3/
IL-1β specks near obstruction sites indicate their epi-
thelial origin, specks were seen embedded in mucus
containing infiltrating neutrophils and other leuco-
cytes, supporting a myeloid origin. A precise contri-
bution from each cell type and/or reduced
mucociliary clearance into the bright intraluminal
staining of obstructed bronchioles could not be
assessed from this study. The localization of NLRP3/
IL-1β specks to and near mucus obstruction sites
irrespectively of their origin nevertheless supported
the hypothesis that NLRP3 inflammasome activation
could be enhanced downstream of mucus obstruction.
IL-1α released from hypoxia-induced necrosis in non-
myeloid cells has been implicated in activation of the IL-
1R/MyD88 axis and initiation of neutrophilic inflamma-
tion [5, 6]. Furthermore, evidence of the NLRP3/IL-1β
pathway activation in a direct association with HIF-1α
was obtained from a rat model of hypoxia and throm-
bosis [23], prompting us to explore an association be-
tween NLRP3/IL-1β specks and local hypoxia. In this
study, GLUT1 was employed as an in situ marker of
hypoxia, which revealed however only a non-significant
trend towards increased apical immunofluorescence near
the mucus plugs. Further studies are thus required to
demonstrate mucus obstruction-associated hypoxia as a
causal factor in airway NLRP3 inflammasome activation.
Given that immune complexes are capable of priming
the NLRP3 inflammasome [24], an additional factor in
NLRP3 inflammasome activation in the βENaC overex-
pression model could be the high concentration of IgG
observed in mucus plaques and plugs.
Consistent with our findings in the lungs of mice
chronically exposed to cigarette smoke [15], the mouse
model of βENaC overexpression revealed bronchiolar
epithelial SPNS2 downregulation, with the notable
Fig. 9 Hypothetical model of NLRP3 inflammasome activation and S1P signalling dysregulation in mucus-obstructed bronchioles. Unobstructed
bronchioles (AIR): NLRP3 is mostly in monomeric state, only background levels of cleaved IL-1β are detected; SPHK1 generates cytosolic S1P, part
of which is exported via SPNS2 for extracellular (inside-out) signalling via S1PRs; SPHK2 generates S1P mostly for intracellular signalling.
Obstructed bronchioles (MUCUS): Increased oligomerization of NLRP3 (inflammasome activation) in either epithelium or infiltrating leucocytes
results in IL-1β cleavage and increased luminal specks of NLRP3/IL-1β; decrease of SPNS2 and SPHK2 results in reduction of extra- and intracellular
S1P signalling
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difference that SPNS2 downregulation in βENaC-
overexpressing mice was localized to mucus obstruction
sites. The intense and colocalized expression of SPNS2
and SPHK1 at the apex of intact bronchiolar epithelia
supports this cell type as a major generator of exogenous
S1P in the airways. Epithelial SPNS2 downregulation at
mucus obstruction sites would lead to reduced S1P ex-
port and subsequent signalling via autocrine/paracrine
ligation of S1PRs on the surface of epithelial and/or
other cell types. A further important finding from this
study was a significant downregulation of bronchiolar
epithelial SPHK2 expression at mucus obstruction sites
in the lung of βENaC over-expressing mice. In contrast
to SPHK1 localization to the cytosol and near the cell
membrane, SPHK2 was localized to mitochondria and
nuclei, suggesting its role in regulation of intracellular
autocrine production of S1P. Taken together, these find-
ings suggest that both the ‘inside-out’ and the intracellu-
lar S1P signalling pathways are dysregulated in the lungs
of βENaC mice, and that these defects are associated
with mucus obstruction. Depending on the subcellular
compartmentalization of S1P generation and the cell
types involved, S1P signalling leads to diverse effects, in-
cluding those offsetting the effects of ceramides [7, 25].
Given that ceramides are increased in muco-obstructive
diseases [9–12] and that they can directly activate the
NLRP3 inflammasome [13], a decrease in S1P signaling
may have a role in amplification of the pro-
inflammatory response.
Conclusions
In conclusion, our results support NLRP3 inflammasome
activation and S1P signalling dysregulation in the lung
disease elicited by βENaC overexpression, and that both
features are associated with mucus obstruction. Our data
suggest that the NLRP3 inflammasome and the S1P sig-
nalling system could represent potential contributors to
pathology and therefore putative therapeutic targets in
CF, COPD and other muco-obstructive respiratory
diseases.
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